Increasing evidence from experimental studies (e.g., glioblastoma C6 cells lines) and some clinical studies have led to randomized-controlled trials incorporating inhibitors of the leptin/ObR axis as adjunctive therapy with established protocols in newly diagnosed and recurrent glioblastoma. The gene discussed is LEP; the disease is glioblastoma.